A group of plaintiffs' attorneys in the Zyprexa multidistrict litigation has objected to a magistrate judge's ruling rejecting its attempt to secure additional fees and has asked the court to award it $3.8 million.
StemCells Inc. has fired back at Neuralstem Inc. over the rival's claims that StemCells deceived the U.S. Patent and Trademark Office in its recent approval of a new patent related to neural stem cell compositions.
Bankrupt vitamin producer Leiner Health Products Inc. has reached a tentative settlement with U.S. investigators over alleged deficiencies in the over-the-counter drugs manufactured at the company's South Carolina plant.
A federal jury dealt a blow Friday to Glycoproducts International Inc., upholding a patent owned by nutritional supplement competitor Mannatech Inc. and awarding treble damages to Mannatech for willful infringement.
Life sciences firm Invitrogen Corp. has struck a deal with the nonprofit Wisconsin Alumni Research Foundation to license three human embryonic stem cell patents that have come under siege by scientists who believe they are invalid.
A $400 billion lawsuit against 32 corporate giants — including Bank of America NA, ChevronTexaco Corp., Dow Chemical Co. and IBM Corp. — for allegedly helping the South African government continue its apartheid policies can move forward because the U.S. Supreme Court lacked a quorum to review a circuit court decision.
The U.S. Securities and Exchange Commission has accused three Florida doctors of illegally trading on inside information about IVAX Corp. and Correctional Services Corp.
The U.S. Supreme Court on Monday refused to hear Apotex Inc.'s request for a rehearing on its patent spat with Abbott Laboratories over the epilepsy drug Depakote, effectively ending the decade-long case in Abbott's favor.
The U.S. Supreme Court and other appellate courts have regularly reduced punitive damage awards that have been deemed unconstitutional for violating defendant due process rights. However, large damage awards have continued to be doled out, leading defense attorneys to urge clearer standards and greater scrutiny for such verdicts in order to avoid a “punishment lottery.”
Recent actions by the U.S. Securities and Exchange Commission allowing universal health care proposals to reach a vote are forcing companies to waste valuable resources on debates that are irrelevant to company business, some experts say.
The Arkansas Supreme Court has ruled that fumes from arsenic-laden chicken litter likely caused a man to develop a rare form of leukemia and has remanded the case for trial.
A special master in the Bausch & Lomb Inc. contact-solution multidistrict litigation has told the company to turn over documents it had argued were protected by attorney-client privilege.
Barr Laboratories Inc.'s bid for U.S. food and Drug Administration approval to make and market a generic version of Bayer Schering Pharma AG's oral birth control product Yasmin has been approved, and the company plans to launch its copycat contraceptive in mid-2008.
A Canadian court has dismissed a long-running patent infringement suit that Johnson & Johnson brought against rival Boston Scientific over one of the medical device maker's coronary stents.
Microsoft Corporation, Buy.com Inc. and SanDisk Corporation were just some of the companies that hired law firms to work on major IP litigation in recent weeks, according to our daily review of court dockets.
Having a formal intellectual property strategy in place is critical to prevent a company from losing its competitive edge in costly and time-consuming lawsuits or, worse yet, from turning over the keys to its business.
Attorneys looking to track down more details on U.S. patents issued this year may have trouble relying on Google Patent Search.
In the wake of the U.S. Food and Drug Administration's backlash against bioidentical hormone replacement drugs, lawmakers introduced a resolution Tuesday opposing the agency's policy restricting women's access to the products.
A Maine state judge has ruled that Eli Lilly & Co.'s objections to the plaintiffs' expert testimony in a wrongful death suit over blockbuster anti-psychotic Zyprexa may be valid but are better addressed to a jury, allowing the case to move forward.
Furthering the fallout over heparin, Medtronic Inc. said Wednesday it was recalling certain disposable medical devices used during cardiac bypass surgery because they may be coated with the tainted blood thinner.